Coherus Oncology, Inc.
Quick facts
Marketed products
- Pegfilgrastim-Cbqv · Oncology
Pegfilgrastim-Cbqv is a pegylated granulocyte colony-stimulating factor (G-CSF) analog that stimulates the proliferation and differentiation of neutrophil progenitor cells to increase circulating neutrophil counts.
Phase 3 pipeline
- CHS-0214 · Oncology
CHS-0214 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells to kill cancer cells. - CHS-1420 · Oncology
CHS-1420 is a bispecific antibody that simultaneously engages CD47 on tumor cells and CD40 on antigen-presenting cells to enhance anti-tumor immunity.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: